SOURCE: Conversant Bio

Conversant Bio

September 10, 2014 04:00 ET

Conversant Bio Releases RA E-Book

Published by Global Leader in Tissue and Cell Samples, Guide Offers Key Information on Rheumatoid Arthritis to Help Researchers

HUNTSVILLE, AL--(Marketwired - Sep 10, 2014) - Conversant Bio, a global leader in supplying the highest-quality human tissue and viable cell samples, today announced it is publishing a guide detailing the basics of rheumatoid arthritis, or RA, for researchers studying the disease. The e-book The Researcher's Ultimate Guide to Rheumatoid Arthritis, is available as a free download at http://www.conversantbio.com/the-researchers-ultimate-guide-to-rheumatoid-arthritis/.

Rheumatoid arthritis is an autoimmune disorder in which the body fails to distinguish its own tissue from foreign pathogens, thus leading to an immune system response that causes joint inflammation, which in turn can result in pain, swelling, cartilage loss, and eventual bone damage. RA affects about 1 percent of Americans, and there is no cure yet for the disease. This new guide offers to researchers a real-world perspective on RA, including:

  • The basics of RA, including symptoms and causes
  • An explanation on how RA is diagnosed and how the disease affects patients' lifestyles
  • Medications and treatments
  • Four research challenges
  • Case studies

"Using high-quality, carefully sourced biospecimens for research can help move rheumatoid arthritis research forward and, ultimately, provide new and better treatments for many autoimmune diseases," says Luke Doiron, chief commercial officer for Conversant Bio. "Our mission with this new e-book is to offer researchers valuable information that can help simplify and accelerate their goals."

To download The Researcher's Ultimate Guide to Rheumatoid Arthritis, visit http://www.conversantbio.com/the-researchers-ultimate-guide-to-rheumatoid-arthritis/.

About Conversant Bio
Conversant Bio provides researchers around the world with hyper-annotated tissue samples in order to conduct informed, cutting-edge investigations into many of today's most problematic diseases. With a large prospective collections network of 36 U.S.-based clinical sites and an IRB-reviewed chain of custody quality control system, Conversant Bio provides the highest-quality samples on time and on budget. For additional information about Conversant Bio's services, visit the company's website at http://www.conversantbio.com.

Contact Information